Comparative effect of daily teriparatide, weekly teriparatide, or bisphosphonate on bone microarchitecture in patients with primary osteoporosis: A HR-pQCT study - Comparative effect of daily teriparatide, weekly teriparatide, or bisphosphonate in patients with primary osteoporosis

agasaki University Hospital0 个研究点目标入组 130 人开始时间: 2016年1月17日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Patients with serious cardiac disorder, serious liver dysfunction, serious kidney dysfunction, diabetes mellitus, endocrine and metabolic diseases which may affect to the bone metabolism, and secondary osteoporosis (e.g., glucocorticoid-induced osteoporosis, rheumatoid arthritis, immobilization osteoporosis) 2)Patients treated with medication which affect to the bone metabolism as follows, i)Glucocorticosteroids (within 6 months before enrollment, or >5mg for over 3 months) except inhaler or nasal drip ii)Anti-cancer drugs iii)Anti-osteoporosis drugs (teriparatide, anti-RANKL antibody, bisphosphonates within 6 months before enrollment, SERMs within 3 months before enrollment, or estrogen preparations) 3)Patients who have contraindication of teriparatide or bisphosphonate 4)Patients who have severe allergy 5)Patients enrolled in other clinical studies in the past 3 months. 6)Patients judged to be inadequate for this study by investigators

发起方

agasaki University Hospital